← Back to Search

Genomic Screening

Targeted Therapy Screening for Lung Cancer

Phase 2 & 3
Recruiting
Research Sponsored by Southwest Oncology Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients must have adequate tumor tissue available, defined as ≥ 20% tumor cells and ≥ 0.2 mm3 tumor volume.
Patients must have pathologically proven non-small cell lung cancer (all histologic types) confirmed by tumor biopsy and/or fine-needle aspiration. Disease must be Stage IV as defined in Section 4.0, or recurrent.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights

Study Summary

This trial will test new targeted cancer therapies against standard of care therapy in order to find more effective treatments.

Who is the study for?
This trial is for adults with Stage IV or recurrent non-small cell lung cancer who've progressed after treatment. They must have a good performance status, adequate tumor tissue for testing, and consent to genomic screening. It's not open to those outside the US or with certain genetic mutations unless they've exhausted standard therapies.Check my eligibility
What is being tested?
The Lung-MAP protocol tests new targeted cancer therapies based on specific biomarkers against standard care. Participants' cancer traits determine their sub-study assignment in this phase II/III trial aiming to approve new treatments through a genomic screening platform.See study design
What are the potential side effects?
While specific side effects depend on the sub-study and therapy received, common issues may include reactions related to immune system activation, typical chemotherapy side effects like nausea and fatigue, as well as potential impacts from novel targeted drugs.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My tumor is large enough and has enough cancer cells for testing.
Select...
My lung cancer is confirmed and is either stage IV or has come back.
Select...
I am fully active or restricted in physically strenuous activity but can do light work.
Select...
I can be screened for the trial either at the time my current treatment stops working or before it stops working.
Select...
I am 18 years old or older.
Select...
I agree to send my tissue samples for specific cancer tests.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Screening Success (Adequate Tissue)
Screening Success (Assignment Success)
Screening Success (Match to Biomarker-Driven Sub-Study)
+3 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Lung-MAP ScreeningExperimental Treatment1 Intervention
This is a screening study and does not have an intervention. LUNGMAP is an overarching umbrella study to which patients are screened and then assigned to a treatment sub-study. The treatment sub-studies are standalone trials and have their own NCT numbers. The Lung-MAP Study is considered a single study under one IND, consisting of the Screening Protocol and multiple sub-studies. Each sub-study protocol operates independently and has its own version date.

Find a Location

Who is running the clinical trial?

Southwest Oncology GroupLead Sponsor
388 Previous Clinical Trials
252,251 Total Patients Enrolled
SWOG Cancer Research NetworkLead Sponsor
394 Previous Clinical Trials
255,610 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,626 Previous Clinical Trials
40,917,643 Total Patients Enrolled

Media Library

Screening Platform (Genomic Screening) Clinical Trial Eligibility Overview. Trial Name: NCT03851445 — Phase 2 & 3
Non-Small Cell Lung Cancer Research Study Groups: Lung-MAP Screening
Non-Small Cell Lung Cancer Clinical Trial 2023: Screening Platform Highlights & Side Effects. Trial Name: NCT03851445 — Phase 2 & 3
Screening Platform (Genomic Screening) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03851445 — Phase 2 & 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this trial popular in the United States?

"This trial is recruiting at New hampshire Oncology Hematology PA-Concord, Norris Cotton Cancer Center-Manchester, Chester County Hospital, and 100 other locations."

Answered by AI

How many people can join this trial before it is considered full?

"In order to move forward, this clinical trial needs to enroll 10000 patients that match the specific inclusion criteria. People from all around New hampshire Oncology Hematology PA-Concord in Concord, New Hampshire and Norris Cotton Cancer Center-Manchester in Manchester, Pennsylvania are encouraged to participate."

Answered by AI

Who else is applying?

What state do they live in?
Alabama
What site did they apply to?
Baptist Memorial Hospital and Cancer Center-Golden Triangle
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
3+

Why did patients apply to this trial?

~4874 spots leftby Jan 2029